Cabozantinib

證據等級: L5

預測適應症: 10 個

Cabozantinib: From Renal Cell Carcinoma to Liposarcoma

One-Sentence Summary

Cabozantinib is an oral multi-kinase inhibitor targeting VEGFR2, MET, AXL, and RET, internationally established for the treatment of advanced renal cell carcinoma and other solid tumors, though not recorded in the local regulatory database. The TxGNN model predicts it may be effective for Liposarcoma as its highest-ranked new repurposing candidate, with 1 clinical trial and 1 publication currently providing direct sarcoma-domain evidence; separately, the drug carries extensive Phase 3 support (L1) across renal carcinoma subtypes.

Quick Overview

Item	Content
Original Indication	Not available in local regulatory database
Predicted New Indication	Liposarcoma
TxGNN Prediction Score	99.83%
Evidence Level	L3
EU Market Status	Not marketed (local registry)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not captured in the local regulatory database. Based on known pharmacological information, cabozantinib is a small-molecule tyrosine kinase inhibitor that simultaneously blocks VEGFR2 (anti-angiogenic), MET (tumour growth and invasion), AXL (immune evasion and EMT), and RET. This multi-target profile distinguishes it from single-pathway VEGFR inhibitors and underpins its clinical superiority in several renal cancer trials (METEOR, CheckMate 9ER, CABOSUN).

Liposarcoma—particularly the MDM2-amplified well-differentiated and dedifferentiated subtypes—is known to overexpress VEGFR2 and demonstrate MET pathway hyperactivation. These molecular features are directly targetable by cabozantinib’s VEGFR2/MET dual inhibition, providing a mechanistically coherent basis for the TxGNN prediction. Additionally, AXL overexpression in dedifferentiated liposarcoma contributes to epithelial-mesenchymal transition (EMT) and resistance to conventional chemotherapy (doxorubicin/ifosfamide); cabozantinib’s AXL inhibitory component may help reverse this resistance mechanism and sensitise tumours to treatment.

The biological overlap between liposarcoma’s known molecular drivers (VEGF/MET/AXL axes) and cabozantinib’s established kinase targets makes this prediction scientifically plausible. The ongoing Phase 2 trial combining cabozantinib with immune checkpoint inhibitors in soft tissue sarcoma further reflects real-world investigator recognition of this rationale, even though dedicated liposarcoma-specific Phase 3 data remain absent.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05836571	Phase 2	Active, Not Recruiting	66	Randomised trial comparing cabozantinib + ipilimumab + nivolumab versus ipilimumab + nivolumab alone in advanced soft tissue sarcoma (including liposarcoma subgroup); assesses whether adding cabozantinib to dual checkpoint blockade improves outcomes

Literature Evidence

PMID	Year	Type	Journal	Key Findings
41770651	2026	Phase 1 Trial	American Journal of Clinical Oncology	Phase 1 study of neoadjuvant cabozantinib combined with radiation therapy in extremity soft tissue sarcomas; demonstrated the safety profile of concurrent use, addressing prior concerns about fistula or visceral perforation risk

EU Market Information

No authorizations are recorded for cabozantinib in the local regulatory database. This likely reflects a data pipeline gap rather than an absence of international approvals; clinicians should consult the EMA SmPC for Cabometyx® (cabozantinib) for full prescribing information.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy — multi-kinase inhibitor (VEGFR2, MET, AXL, RET); not a conventional cytotoxic agent
Myelosuppression Risk	Low to moderate (less myelosuppressive than cytotoxic chemotherapy; thrombocytopenia and neutropenia reported; Grade 3–4 haematological events less common than with platinum or taxane regimens)
Emetogenicity Classification	Low (oral administration; nausea is common but typically Grade 1–2; no routine prophylactic antiemetic required per low-emetogenicity guidelines)
Monitoring Items	Complete blood count (CBC), liver function (ALT/AST/bilirubin), renal function (creatinine, urea), blood pressure (hypertension is a class effect), thyroid function, wound healing assessment, urine protein
Handling Protection	Standard oral antineoplastic precautions apply; cytotoxic handling guidelines (PPE, dedicated dispensing) are recommended per institutional policy

Safety Considerations

Please refer to the SmPC for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Cabozantinib’s mechanistic profile (VEGFR2/MET/AXL inhibition) aligns with known molecular drivers of liposarcoma, and the TxGNN model assigns a near-maximal prediction score of 99.83%. However, existing evidence is currently limited to one Phase 2 trial enrolling a broad soft tissue sarcoma population (with liposarcoma as a subgroup) and a single Phase 1 safety study—placing the liposarcoma indication firmly at L3. This is insufficient for a direct clinical recommendation but justifies a structured research programme.

Separately, the data pack reveals that cabozantinib has L1-level evidence for renal carcinoma (multiple completed Phase 3 trials: METEOR, CheckMate 9ER, COSMIC-313), representing its most evidence-rich pathway and the likely basis for its international regulatory approvals.

To proceed toward a liposarcoma indication, the following is needed:

A dedicated Phase 1b/2 basket or expansion cohort trial in liposarcoma (particularly MDM2-amplified subtypes) evaluating cabozantinib monotherapy or combination with immune checkpoint inhibitors
Biomarker profiling of target patient population to confirm VEGFR2, MET, and AXL expression levels in liposarcoma tissue
Subgroup analysis from NCT05836571 (once results are available in 2026) to extract liposarcoma-specific response data
Full mechanism of action documentation and local regulatory submission to populate the safety database
Review of the EMA SmPC for Cabometyx® to complete the contraindication and DDI profiling currently listed as data gaps
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.